Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym004 with Platinum-doublets in Stage IV NSCLC
NCT02083679Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Jul 2014
- Primary completion
- Aug 2015
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of futuximab + modotuximab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by EMD Serono. Primary endpoint: Dose Limiting Toxicities. Started Jul 2014; status: terminated.
02
Drugs
futuximab + modotuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02083679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083679.